Brief introduction of FDA approved drugs on the market in October 2015

In October, the FDA approved several drugs, some of which will be listed in the history of drug development Let's read it for you 1、 Approval date of keytruda (pembrolizumab): October 2, 2015 FDA approved the use of keytruda (pembrolizumab) in the treatment of advanced non-small cell lung cancer with metastasis At the same time, FDA also approved a characteristic diagnostic reagent pd-l1ihc22c3pharmdxtest, which is mainly used to test the level of PD-L1 protein expressed in vivo, so as to judge whether keytruda can be used in the treatment of NSCLC Keytruda mainly targets the metabolism pathway of PD-L1 protein in cancer cells, and acts as a blocker to block the metabolism and proliferation of cancer cells The drug was launched by Merck & Co and its corresponding diagnostic reagent was launched by Dako North America Inc 2、 Aristada (aripiprazole laurox IL) approval date: October 5, 2015 FDA approved the use of aristada sustained-release injection in the treatment of schizophrenia, the drug can be extended to 4 to 6 weeks This long-term treatment can help improve the quality of life of patients The main symptoms of schizophrenia are auditory hallucination, paranoia and cringe The main risk of this drug is that it increases the number of deaths associated with Alzheimer's disease, so special attention should be paid to remind patients of the risks and precautions 3、 Opdivo (nivolumab) approval date: October 8, 2015 FDA approved the expansion of opdivo (nivolumab) in the treatment of non-small cell lung cancer (NSCLC), from the treatment of squamous NSCLC to non squamous NSCLC, mainly for the treatment of late metastasis and follow-up chemotherapy with platinum drugs The drug was introduced by Bristol Myers Squibb 4、 Praxbind (idarubizumab) approval date: October 16, 2015 FDA approved praxbind (idarubizumab) for blood thinning effect in the use of pradaxa (dabigatran) This is the first drug to target pradaxa's (dabigatran) blood thinning effect Pradaxa is a life-saving drug in emergency treatment, while praxbind reverses some anticoagulant effects of pradaxa to regulate blood biochemical indexes and rheological characteristics when necessary The drug was introduced by bringer Ingelheim 5、 Coagadex (agglutination factor X) approval date: October 20, 2015 FDA approved coagadex for the treatment of hereditary coagulation factor X deficiency Coagadex is the agglutinate of hereditary clotting factor X, and is the first orphan drug for the treatment of the above diseases In normal people, agglutinin x assists in enzyme catalyzed coagulation, but for a small number of people who are born without the substance, there is a high risk of bleeding in specific situations Therefore, the newly approved coagadex has made up for this problem, but the corresponding diseases of the drug are mainly for a few genetic diseases, which are not many, so it can only be approved in the form of orphan drugs Coagadex was launched by bioproducts Laboratory Limited in the UK 6、 Veltassa (patiromer oral suspension) approval date: October 21, 2015 FDA approved patiromer oral suspension for the treatment of hyperkalemia If the blood potassium is too high, the heart rhythm will be damaged, even fatal The elimination of blood potassium is usually through the kidney However, when the renal function is abnormal, it may lead to the increase of blood potassium The occurrence of abnormal function is generally acute and chronic kidney disease, heart failure, especially when taking anti Angiotension aldosterone system drugs to regulate blood pressure or body fluid balance Therefore, maintaining a proper level of blood potassium is conducive to human health Veltassa is mainly used to absorb potassium ions in gastrointestinal tract to reduce absorption, and then reduce potassium intake The drug was introduced by relypsa Inc 7、 Approval date of a new treatment plan for pancreatic cancer: October 22, 2015, FDA approved the use of onivyde (irinotecan liposome injection) combined with fluorouracil and calcium folinate in patients with advanced metastatic pancreatic cancer Such patients usually do not recommend such treatment plan until gemcitabine chemotherapy fails Early diagnosis of pancreatic cancer is not very good, and surgery is almost impossible to eradicate, especially when the space for treatment options after metastasis is getting narrower The drug is approved as an orphan drug In the process of use, the drug mainly has serious neutropenia and diarrhea and other adverse reactions, which should be paid special attention to The drug was launched by Merrimack pharmaceuticals Inc 8、 Approval date of yondelis (trabectedin): October 23, 2015 FDA approved the use of yondelis (trabectedin) in the treatment of soft tissue sarcomas such as liposarcoma and leiomyosarcoma, and mainly used for patients whose operation cannot be eradicated or who have advanced metastasis and who have used anthracycline chemotherapy It is very difficult to eradicate advanced malignant sarcoma, so the approval of this drug is only a choice for it In clinical trials, compared with the chemotherapy regimen of nitramide, it can prolong the tumor expansion period of patients by about 3 months At the same time, the side effects of the drug are still serious, such as neutropenia, rhabdomyolysis, liver injury caused by blood toxicity, heart failure caused by cardiomyopathy, so we should be careful in the use process The drug was introduced by Janssen products of Raritan 9、 Strensiq (asfotasealfa) approval date: October 23, 2015 FDA approved strensiq (asfotasealfa) for the treatment of hypophosphatase in perinatal, infants and adolescents This is the first drug to treat a specific population of hypophosphatase The drug is used once every 3 to 6 weeks The drug works mainly by replacing enzymes responsible for normal bone mineral composition The drug was launched by alexion pharmaceuticals Inc 10、 Imlygic (talimogenelaherparepvec) approval date: October 27, 2015 FDA approved the use of imlygic (talimogenelaherparepvec) in the treatment of melanoma of skin and lymph nodes This is the first FDA approved oncolytic virus The drug was launched by biofex Inc., a subsidiary of Amgen For more information about new drugs, please pay attention to www.yaozh.com Note: the intellectual property rights of the above articles are owned by yaozhi.com If you need to reprint, please indicate the source and the link of this article.